Czech cybersecurity and antivirus firm Avast plans London IPO, seeking around $200M at a ~$4B valuation
LONDON (Reuters) - Avast, the world's largest consumer antivirus supplier by customers, said on Thursday it will apply to list its shares on the London Stock Exchange …
Context & Ripple Effects
Avast's listing plans cap a decade-long consolidation run: the Czech firm, founded in 1988 and profiled as a survivor of the McAfee/Symantec era, had already absorbed rival AVG in a $1.3 billion acquisition in 2016 to become the world's largest consumer antivirus supplier by customers. A London float — rather than a US one — is the notable venue choice for a company of this scale.
The IPO itself landed a month later: Avast raised $814 million but priced below its ~$4 billion target at a $3.1 billion-plus valuation, a discount that frames the whole arc — because by 2021 the listed company was in advanced merger talks with NortonLifeLock at a market value near $7.2 billion.
First-order effects
- Avast's existing shareholders get a liquid exit and a public currency, while the ~$200 million raise gives the company listed-equity funding for its post-AVG consumer security platform.
- The London Stock Exchange lands one of its largest tech listings of the period, a direct win in its competition with US exchanges for European software issuers.
Second-order effects
- Pricing below the ~$4 billion ask at $3.1 billion-plus signals that public investors were discounting consumer antivirus growth — pressure that pushes the consolidated freemium security market toward further roll-up rather than standalone expansion.
- Rivals in consumer security face a listed Avast with acquisition currency, raising the odds of follow-on M&A in a segment already reshaped by the AVG deal.
Third-order effects
- The pattern — consolidate the freemium antivirus base, list, then merge — points toward consumer cybersecurity concentrating into a handful of scaled portfolios, culminating in the NortonLifeLock combination talks.
- For European exchanges, Avast's float becomes the reference case for whether London can retain large homegrown software issuers that would once have defaulted to New York.
The trend: Consumer antivirus is consolidating from a crowded freemium field into a few listed platforms, with Avast's London float marking the step from private roll-up player to public merger currency.